Cannabis Stocks News
Interactive Brokers Advertisement
Home > Boards > Canadian > Biotechs >

Breathtec Biomedical Inc. (BTHCF)

Add BTHCF Price Alert      Hide Sticky   Hide Intro
Moderator: shell3, hoyowasobo
Search This Board: 
Last Post: 8/22/2017 12:00:31 PM - Followers: 54 - Board type: Free - Posts Today: 0

FEBURARY 5th 2017 

Issued and outstanding common shares 54,752,024 

Warrants outstanding 26,029,676 

Stock options outstanding. 3,495,000

Breathtec Biomedical, Inc. (“Breathtec”) was formed to propel innovative research in the area of breath analysis as a medical screening tool. Our efforts are aimed at leading the development of commercially viable methods for the early screening of diseases such as lung & breast cancers, neurodegenerative diseases (eg: Alzheimer’s / Parkinson’s), tuberculosis, diabetes, liver disease and more.

Our primary avenue of investigation is focused on innovation and advances in the field of specialized mass spectrometry.

The principal market opportunity arises from the potential of low-cost, non-intrusive diagnostic screening in general medical practice which could lead to notable advances in early detection of major cancers and other life-altering diseases.

Regular screening using a simple breath test, could lead to significant advancements in remedial treatment protocols targeting major improvements in survivability and life


High-Field Asymmetric Waveform Ion Mobility Spectrometry (FAIMS)

Function: Compounds (Ions) are Separated by Mobility

  • Function of the size, shape, charge
    Direct, real-time separation
    Continuous sample introduction

An Ion filter – only molecules of interest are allowed to be detected

FAIMS Technical Overview

Breathtec Biomedical aims to assist the development of novel instrumentation and methodologies for high-field asymmetric waveform ion mobility spectrometry(FAIMS). FAIMS can be performed on a standalone device, or, more prominently, coupled to a mass spectrometer (MS). FAIMS is a separation technique which allows continuous sample introduction, enabling direct, real-time analysis.

FAIMS (or differential mobility spectrometry, DMS) involves separation based on the inherent differences in an ion’s mobility in high and low electric fields, and can be performed at atmospheric pressure and room temperature

Breathtec Biomedical Closes License of NA-NOSE Technology for Disease Detection

Corporate Presentation

Company filings


Guy LaTorre, Chief Executive Officer

Mr. LaTorre brings over 25 years of experience in the development and commercialization of medical devices and consumer products in a startup company environment. Guy was a co-founder and Vice President of Business Development at Novamin Technology Inc. where he was responsible for identifying and managing the Company’s relationships with its key clients in the dental products field, including product development of in-office and at-home use products using the company’s proprietary ingredient. In that role, he formed and managed product development partnerships between NTI and the leading marketers of professional dental products, including Dentsply Corp, 3M Corp, Sultan Healthcare, Sunstar and others until the company was sold to GlaxoSmithKline (GSK) in 2010 for USD $135 million.

Previously, Guy was the Director of Scientific Affairs at USBiomaterials Corp. which developed and sold synthetic bone grafting products for use in dental, head, neck and orthopedic surgeries. His responsibilities also included product development, manufacturing and business development activities. Prior to USBiomaterials, Guy was the Laboratory Manager of the University of Florida Advanced Materials Research Center where he was responsible for the managed transfer of licensed university technologies to private startup companies. Guy has been author or co-author of over fifty scientific publications and holds seven US patents with associated filings worldwide.



Kal Malhi, President and Director

Mr. Malhi is a Canadian entrepreneur and businessman. He is a retired member of the Royal Canadian Mounted Police and also President of BullRun Group, a private investment company specializing in early stage business development.

His interest in issues of individual rights aligned with public safety through law enforcement initiatives shaped his vision in the founding of Cannabix Breathalyzer, Inc where Mr. Malhi was instrumental in growing the company from a startup to a publicly traded company with a valuation in excess of $30 million dollars.

This successful enterprise broadened his interest in breath analysis and the extraordinary opportunities in the sector. His extensive network of contacts and personal relationships has enabled him to assemble a growing team aimed at unearthing the potential for commercial breath analysis applications as a new and potentially high growth sector


Raj Attariwala, MD, PhD., Lead Engineer

Dr. Attariwala is a dual board certified Radiologist and Nuclear Medicine physician certified in both Canada and the United States. He received his formal medical training at University of British Columbia with periods of specialized medical training at Memorial Sloan Kettering Cancer Centre (New York), UCLA and USC. He holds a doctorate in Biomedical Engineering from Northwestern University (Evanston, IL).

Dr. Attariwala is a practicing physician in British Columbia and owner of AIM medical imaging. He has pioneered advances in the field of whole body medical imaging and authored numerous publications and presented at international medical conferences on whole body imaging and cancer detection.

Dr. Attariwala has extensively investigated breath testing applications and efficacy in a related role at Cannabix Technologies Inc. where he developed a breath testing system for drug impairment.


Richard A. Yost Ph.D., Scientific Advisor

Dr. Yost, Col. Allen R. & Margaret G. Crow Professor and Head of Analytical Chemistry at the University of Florida received his B.S. degree in Chemistry from the University of Arizona in 1974. In 1975 he pursued an NSF graduate fellowship at Michigan State University focusing on electronics and computerized instrumentation. He received his Ph.D. in 1979 and assumed the position of Assistant Professor at the University of Florida and went on to become head of the Analytical Chemistry Division.

Dr. Yost’s research has involved over 100 graduate students funded by over $40 million in research grants, and has published over 160 papers and 16 patents. Over $30 billion worth of instruments have been sold based on these patents.

He serves as a member of the Florida Board of Governors (Regents) and as the Chair of the Advisory Council of Faculty Senates of Florida. He is past Chair of the UF Faculty Senate and served on the UF Board of Trustees. He served as Treasurer and Secretary of the American Society for Mass Spectrometry, and on the editorial boards of The Journal of the American Society for Mass Spectrometry and The International Journal of Mass Spectrometry.

Prof. Hossam Haick, Consultant

Dr. Haick is a full Professor in Chemical Engineering and Nanotechnology at the Technion Israel Institute of Technology and an expert in the field of nanotechnology and non-invasive disease diagnosis.  Dr. Haick is the recipient of the prestigious Marie Curie Excellence Award, ERC Award, and the FP-7 and Horizon 2020 consortium Awards. He is also the recipient of more than 56 international honors and prizes for his achievements. Prof. Haick has published over 170 articles and serves on the editorial board of several peer-reviewed journals, and is a senior scientific advisory member of several national and international companies and institutes. Prof. Haick’s ground-breaking research has led to the development of the NA-NOSE nanotechnology-based breath test technology for detecting biomarkers of disease. Certain disease conditions produce chemicals called volatile organic compounds (VOCs), which easily evaporate into the air and produce a discernible scent profile. The Na-NOSE chip detects the unique “signature” of VOCs in exhaled breath. As a consultant to Breathtec, Prof. Haick will guide the company’s development of the NA-NOSE disease detection system and design the clinical trials to be undertaken by the company.


Michael T. Costanzo, Ph.D., Chief Technical Officer

Dr. Costanzo enjoys a passion for science that has directed his career path firmly into the field of analytical chemistry. Over the past five years he has investigated a variety of advanced experimental methodologies and instrumentation with the Yost Research Group at the University of Florida. During this period he utilized UV spectroscopy to help in standardizing procedures for manufacturing respiratory medications, employed novel ion mobility spectrometric techniques and devices to analyze exhaled breath, and performed multiple metabolomics studies of melanoma. Through his efforts, he acquired a vast knowledge of analytical techniques and methodologies and an immense desire for scientific progress.

Previously, Costanzo obtained his Bachelor of Science in chemistry at the State University of New York (Buffalo). During this period he conducted research under Dr. Troy Wood utilizing mass spectrometry to examine products of enzymatic protein digestion in the interest of studying metabolic markers of autism in children. Upon graduation in 2010 he moved to the University of Florida for Ph.D. studies and as a result of his efforts has recently joined with Breathtec Biomedical to propel his own bioanalytical research through the development of revolutionary clinical devices utilizing his background in ion mobility, mass spectrometry, and exhaled breath analysis.



Suite 890, 789 West Pender Street
Vancouver, British Columbia, Canada V6C 1H2 


Breathtec Biomedical Provides Corporate Overview


-- Company offers update of events and outlook for near term opportunity


VANCOUVER, BRITISH COLUMBIA – October 17, 2016 – Breathtec BioMedical, Inc(CSE: BTH.CN) (CNSX: BTH) (CSE: BTH) (XFRA: BTI) (OTCQB: BTHCF) (the “Company” or “Breathtec”), a medical diagnostics company focused on developing, in-licensing and commercializing proprietary, innovative and best-in-class breath analysis devices for the early detection of infectious and life threatening diseases wishes to address recent corporate events and to provide an update regarding its immediate outlook and future plans.


In response to recent volatility in its share price, the Company notesthat fluctuations are an example of development stage market volatility which in Management’s opinion should be viewed in the context of the Company’s underlying financial health and strength of its product portfolio. Breathtec maintains a healthy working capital position of $1.3M. Additionally, management of the Company have voluntarily escrowed a significant number of shares with no insider sales having occurred or contemplated.


Breathtec’s technology portfolio continues to move ahead with all licensing and development agreements in-place and a number of ongoing achievements and development phases underway. A brief summary of recent and ongoing activities is summarized below. 


FAIMS Technology:

Breathtec continues to progress its flagship FAIMS technology with the recent completion of a V2 prototype breathalyzer design. The latest design has significant advances over the previous prototype including larger dynamic range and improved efficiency in the square waveform generator, greater sensitivity achievable by the detector, improvements in the design, implementation of the novel ionization source, and is overall more than 10X smaller than the V1 prototype.The current design is well under development and includes features to allow for the addition of an onboard processor, touch screen and rechargeable battery in a handheld device configuration.


NaNose Technology:

The Company anticipates receiving requisite IRB regulatory approval in order to commence clinical studies in Surrey, BC, Canada this month. The study has been designed to determine if the NaNose technology can identify differences in the breath signatures of patients with bacterial infections versus patients with viral infections. The ability to differentiate between bacterial versus viral infections at the Point of Care is anticipated to greatly assist physicians with treatment recommendations which could significantly and positively impact the excessive prescribing and resulting overuse of antibiotic-based treatments.


Regulatory Pathway:

Management has engaged regulatory consultants with extensiveexperience in medical device and in vitro diagnostics strategies to evaluate potential regulatory options to propel both the FAIMS and NaNose technology platforms to market. The Company has furtherengaged experienced product development consultants to initiate the design controls, and quality systems processes to meet regulatory approval and to lead the establishment of product manufacturing protocols as a precursor to commercialization.


Professional Collaboration:

Dr. Michael Costanzo, Breathtec’s CTO recently gave a well-received presentation Developing a Point-of-Care Device for Breath Analysis Utilizing FAIMS and FAIMS/MS,” to a prestigious group of leading experts in the field of breath analysis in Zurich, Switzerland. At the event, Dr. Costanzo affirmedBreathtec anticipates completion of a prototype of the FAIMS device in Q4 of 2016 and will work alongside our partner to advance the technology towards the clinic.” Dr. Costanzo’s presentation can be found here:


Company CEO, Guy LaTorre comments, “We earnestly appreciate the continued interest and support of all our stakeholders, partners, affiliates and shareholders alike. As such, I wanted to take this opportunity to recap our continued technical achievements as we continue to be motivated daily with overwhelmingly positive feedback as regards the need for a Point-of-Care device such as ours as a means to save countless healthcare dollars and untold numbers of lives in the foreseeable future. These factors compel us to move ahead as quickly as possible with this exciting endeavor and we sincerely thank our supporters for the means to do so.”



"Guy LaTorre"
CEO & Director


For further information, please contact: 

Kal Malhi

President & Director

Breathtec BioMedical, Inc




Suite 890, 789 West Pender Street Vancouver, British Columbia, Canada V6C 1H2

Breathtec Biomedical Announces Plans for Breath Analysis Clinical Trials at Canadian Tech Facility

--City of Surrey’s Health &Technology District to host Breathtec’s in-licensed Na-Nose study for disease detection.

VANCOUVER, BRITISH COLUMBIA June 28, 2016 Breathtec BioMedical, Inc. (CSE: BTH) (CNSX: BTH) (XFRA: BTI) (OTCQB: BTHCF) (the “Company” or “Breathtec”), a medical diagnostics company focused on developing, in-licensing and commercializing proprietary, innovative and best-in- class breath analysis devices for the early detection of infectious and life threatening diseases, is holding a press conference today to announce plans for the commencement of the company’s clinical trial program at Innovation Boulevard located in Surrey, British Columbia.

Today’s announcement marks the beginning of an intensive research review into NA-NOSE, an advanced stage, nanotechnology-based breath analysis device from the Technion Israel Institute of Technology which has been in-licensed by Breathtec. The system has been developed to detect the volatile biomarkers of diseases from exhaled breath, and Breathtec has chosen the Province of British Columbia and the City of Surrey to hold its clinical trials for selected respiratory infections at the Health & Technology District on Innovation Boulevard.

“Breathtec’s exciting technology, developed in Israel, is going through the highest quality clinic trials right here in British Columbia,” said Minister of Technology, Innovation and Citizens’ Services, Amrik Virk. “We have a vibrant tech sector attracting companies from clean tech, to information and communications systems, to life sciences – this kind of innovative work is a key part of our diversified economy.”

“The City of Surrey supports the development of health technologies and we welcome Breathtec Biomedical to our growing stable of health technology specialist firms,” said Mayor Linda Hepner. “The addition of Breathtec is another example of how the City of Surrey is committed to working together to help take innovative science and technology ideas off the drawing board and turning them into real working solutions that will improve the quality of life for all.”

Breathtec CEO Mr. Guy LaTorre states, “We are delighted to come to the City of Surrey, British Columbia and to have the opportunity to access such a world-class facility and team. The NA-NOSE device is an exciting new late stage technology that has already been clinically proven in the early detection of cancer and has the potential to change the way we diagnose respiratory diseases which will be our company’s focus.”

During the event, NA-NOSE lead researcher Professor Hossam Haick will demonstrate how the nanotechnology-based breath analysis system is used for screening of potentially life-threatening diseases. The licensed technology will be clinically evaluated as a non-invasive point of care device for early detection of community and hospital based infections such as Streptococcus; Methicillin resistant (MRSA); Staphylococcus; Enterococcus; Vancomycin resistant (VRE); Pneumococcus; Hemophilus influenza (HiB); Chickenpox; and the common cold, etc.

Press Conference Tuesday, June 28th at 11 a.m. (PDT), 2 pm (EDT).
Where: City Centre 1, 13737 96th Avenue, HealthTech Innovation Hub (2nd Floor), Surrey, Canada. In Attendance:

? Honourable Minister Amrik Virk, Minister of Technology, Innovation and Citizens’ Services

?  Mayor Linda Hepner, City of Surrey

?  Guy LaTorre, Chief Executive Officer, Breathtec Biomedical

?  Dr. Hossam Haick, Professor in Chemical Engineering and Nanotechnology at Technion -Israel

Institute of Technology (product demonstrations)

?  Dr. Raj Attariwala, MD, PhD., Lead Engineer, Breathtec Biomedical

Innovation Boulevard is an agile partnership of health, business, higher education and government coming together and creating new health technologies to improve peoples’ lives through a shared vision to achieve innovative results, improve health outcomes for patients, implement intelligent solutions for the health care economy, attract talented clinicians and researchers, and to grow companies in the health care technology and services sector. Find out more at:


"Guy LaTorre" CEO & Director

For further information, please contact:

Kal Malhi
President and Director
Breathtec BioMedical, Inc 

Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
BTHCF News: Breathtec BioMedical CTO Delivers Presentation to International Science Community 03/17/2017 10:00:00 AM
#2063  Sticky Note Commercial Adoption of Ion Mobility Technology Drives Multi-Omics Application shell3 07/23/17 11:38:00 AM
#1433  Sticky Note DD Links hoyowasobo 03/17/17 06:43:30 AM
#2111   sure... just like the eclipse today! all signs hoyowasobo 08/22/17 10:03:44 AM
#2110   That's what I was thinking... smoki 08/22/17 09:23:01 AM
#2109   Maybe it is a sign that things are iluv blozf 08/22/17 09:16:04 AM
#2108   Ok now... number's gone on both (Breath/Torino) Ticker smoki 08/22/17 09:11:12 AM
#2107   On my broker summary page breath tec and smoki 08/21/17 10:26:41 PM
#2106   I didn't notice anything on Scottrade RolandDoe 08/21/17 08:18:39 PM
#2105   Seems to be just fine for me through Jaynes19 08/21/17 06:42:37 PM
#2104   Schwab smoki 08/21/17 06:38:13 PM
#2103   Hey Smoki...not exactly sure what you mean..can you RolandDoe 08/21/17 05:37:00 PM
#2102   Can not access BTHCF on my brokerage account today smoki 08/21/17 03:56:18 PM
#2101   Gonna Happen .... Hell Yeah!! smoki 08/17/17 11:59:41 PM
#2100   Accumulation of Cheap Shares? Very Good Idea. Period. AMG 08/17/17 11:54:59 PM
#2099   I can picture it now... AMG 08/17/17 11:36:28 PM
#2098   Maybe we need Kal back to get something iluv blozf 08/17/17 11:34:09 PM
#2097   I'm looking forward to the day we hit RolandDoe 08/17/17 10:10:31 AM
#2096   Looking forward to the Day when All He'll smoki 08/17/17 12:16:53 AM
#2095   Big volume fellas!!! Lol...we need something RolandDoe 08/10/17 01:32:46 PM
#2094   Mgt? smoki 08/10/17 02:07:20 AM
#2093   ...or zero shares all day long. No DiamondInTheRough 08/09/17 11:34:10 AM
#2092   .09 today or .10 smoki 08/09/17 10:38:22 AM
#2091   So funny to see this hit .046 ...someone RolandDoe 08/04/17 11:37:42 AM
#2088   I was just thinking the same thing! It spliffythecat 08/03/17 06:47:40 PM
#2087   Not a bad close...let's get some real volume RolandDoe 08/03/17 04:10:26 PM
#2086   Molecule to Metabolic shell3 08/02/17 09:29:26 AM
#2085   This is great news! spliffythecat 08/02/17 09:20:25 AM
#2084   Hand-Held is done - BLOZF BETA 3.0 is shell3 08/02/17 09:09:56 AM
#2083   54,752,024 OUTSTANDING August 1, 2017 shell3 08/02/17 08:59:51 AM
#2082   Careful - Your impatience is showing.. spliffythecat 08/02/17 08:59:06 AM
#2081   Meaning it works and ready to pick a Target shell3 08/02/17 08:56:33 AM
#2080   Management has recently presented our plans to the shell3 08/02/17 08:51:14 AM
#2079   The Company is in the process of identifying shell3 08/02/17 08:49:37 AM
#2078   The R&D Team initiated some real time breath shell3 08/02/17 08:48:23 AM
#2077   Could have made a lot of $$$ this smoki 08/02/17 01:09:14 AM
#2076   Dead stock iluv blozf 08/01/17 11:07:53 PM
#2075   Markets at all time High's today ....and this smoki 08/01/17 10:59:46 PM
#2074   We shall see I guess. RolandDoe 07/31/17 06:09:34 PM
#2073   Don't hold your breath Pun intended Mcfish 07/31/17 06:01:42 PM
#2072   Well if Blozf has a beta 3.0 and RolandDoe 07/31/17 02:26:14 AM
#2071   Pushing right down to $0.075 CAD. What DiamondInTheRough 07/26/17 11:52:39 AM
#2070   Relax, it's temporary. :) I have confidence that spliffythecat 07/25/17 10:58:23 AM
#2069   Just when you think it can't go down smoki 07/25/17 10:29:10 AM
#2068   bthcf as blozf will never blow. blozfs competition hoyowasobo 07/24/17 06:14:19 AM
#2067   Blozf ....easily. RolandDoe 07/23/17 08:29:56 PM
#2066   Who do you think will Blow first...Blo/Blozf or Bthcf? smoki 07/23/17 03:55:54 PM
#2065   Scientists in the Streets shell3 07/23/17 12:14:19 PM
#2064   And just before PITTCON 2017 shell3 07/23/17 12:04:02 PM
#2063   Commercial Adoption of Ion Mobility Technology Drives Multi-Omics Application shell3 07/23/17 11:38:00 AM
#2062   It's Summer....testing? smoki 07/22/17 04:55:32 PM
#2061   youll find that remark in almost every companys hoyowasobo 07/22/17 03:22:45 PM
#2060   and of course dilution is coming....... namah sivaya 07/22/17 02:49:16 PM